Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate
OSAKA, Japan–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited TSE: 4502, (“Takeda”) today announced that its purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate (TAK-426) has progressed...